BE2015C033I2 - - Google Patents

Download PDF

Info

Publication number
BE2015C033I2
BE2015C033I2 BE2015C033C BE2015C033C BE2015C033I2 BE 2015C033 I2 BE2015C033 I2 BE 2015C033I2 BE 2015C033 C BE2015C033 C BE 2015C033C BE 2015C033 C BE2015C033 C BE 2015C033C BE 2015C033 I2 BE2015C033 I2 BE 2015C033I2
Authority
BE
Belgium
Application number
BE2015C033C
Other languages
French (fr)
Original Assignee
Hormos Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34837941&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2015C033(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Hormos Medical Ltd filed Critical Hormos Medical Ltd
Publication of BE2015C033I2 publication Critical patent/BE2015C033I2/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/075Ethers or acetals
    • A61K31/085Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30Dietetic or nutritional methods, e.g. for losing weight
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/075Ethers or acetals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/24Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30Oestrogens
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23VINDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BE2015C033C 2004-02-13 2015-06-10 BE2015C033I2 (en, 2012)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/777,211 US8236861B2 (en) 2004-02-13 2004-02-13 Method for enhancing the bioavailablity of ospemifene

Publications (1)

Publication Number Publication Date
BE2015C033I2 true BE2015C033I2 (en, 2012) 2024-08-08

Family

ID=34837941

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2015C033C BE2015C033I2 (en, 2012) 2004-02-13 2015-06-10

Country Status (23)

Country Link
US (5) US8236861B2 (en, 2012)
EP (1) EP1713458B1 (en, 2012)
JP (2) JP5577011B2 (en, 2012)
CN (1) CN1925847A (en, 2012)
AT (1) ATE387910T1 (en, 2012)
AU (1) AU2005211958B2 (en, 2012)
BE (1) BE2015C033I2 (en, 2012)
BR (1) BRPI0507661A (en, 2012)
CA (1) CA2556089C (en, 2012)
CY (2) CY1111014T1 (en, 2012)
DE (1) DE602005005165T2 (en, 2012)
DK (1) DK1713458T5 (en, 2012)
ES (1) ES2302177T3 (en, 2012)
FR (1) FR15C0041I2 (en, 2012)
HU (1) HUS1500030I1 (en, 2012)
LT (1) LTC1713458I2 (en, 2012)
LU (1) LU92736I2 (en, 2012)
MX (1) MXPA06009274A (en, 2012)
NO (2) NO337656B1 (en, 2012)
PL (1) PL1713458T3 (en, 2012)
PT (1) PT1713458E (en, 2012)
RU (1) RU2385716C2 (en, 2012)
WO (1) WO2005077350A1 (en, 2012)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8236861B2 (en) 2004-02-13 2012-08-07 Hormos Medical Corporation Method for enhancing the bioavailablity of ospemifene
US8642079B2 (en) * 2004-02-23 2014-02-04 Hormos Medical Corporation Solid formulations of ospemifene
PT2275098E (pt) 2004-05-04 2012-08-29 Hormos Medical Ltd Novas formulações orais de ospemifeno
US8758821B2 (en) * 2004-05-04 2014-06-24 Hormos Medical Ltd. Oral formulations of ospemifene
EP1948148A2 (en) * 2005-11-09 2008-07-30 Hormos Medical Ltd. Formulations of fispemifene
US8158828B2 (en) * 2005-11-28 2012-04-17 Gtx, Inc. Nuclear receptor binding agents
BRPI0620520A2 (pt) * 2005-11-28 2011-11-16 Gtx Inc agentes ligantes de receptores nucleares
US8637706B2 (en) 2005-11-28 2014-01-28 Gtx, Inc. Nuclear receptor binding agents
US9409856B2 (en) 2005-11-28 2016-08-09 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US8546451B2 (en) 2005-11-28 2013-10-01 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
WO2008099060A2 (en) * 2007-02-14 2008-08-21 Hormos Medical Ltd Methods for the preparation of fispemifene from ospemifene
JP5363344B2 (ja) * 2007-02-14 2013-12-11 ホルモス メディカル リミテッド 治療に有用なトリフェニルブテン誘導体の調製方法
US9624161B2 (en) 2009-02-23 2017-04-18 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9427418B2 (en) 2009-02-23 2016-08-30 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
WO2014060639A1 (en) 2012-10-19 2014-04-24 Fermion Oy A process for the preparation of ospemifene
CN103739456A (zh) * 2013-12-03 2014-04-23 镇江圣安医药有限公司 2-(对-((z-4-氯-1,2-二苯基-1-丁烯基)苯氧基)乙醇的新型衍生物及其应用
GR1009542B (el) 2018-04-25 2019-06-07 Φαρματεν Α.Β.Ε.Ε. Καψουλα μαλακης γελης που περιλαμβανει εναν εκλεκτικο ρυθμιστη οιστρογονικων υποδοχεων
SMT202300399T1 (it) 2018-05-11 2024-03-13 Xenon Pharmaceuticals Inc Metodi per migliorare la biodisponibilità e l’esposizione di un attivatore di canale potassio voltaggio-dipendente
EP4523687A3 (en) 2019-10-10 2025-05-21 Xenon Pharmaceuticals Inc. Solid state crystalline forms of a selective potassium channel modulator
BR112022008580A2 (pt) 2019-11-08 2022-08-09 Xenon Pharmaceuticals Inc Métodos para tratar transtornos depressivos
CA3207191A1 (en) 2021-02-09 2022-08-18 Simon Neil PIMSTONE Voltage-gated potassium channel opener for use in treating anhedonia

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9007052D0 (en) * 1990-03-29 1990-05-30 Skua Investments Ltd Pharmaceutical formulations
GB9207437D0 (en) * 1992-04-03 1992-05-20 Orion Yhtymae Oy Topical administration of toremifene and its metabolites
GB9418067D0 (en) * 1994-09-07 1994-10-26 Orion Yhtymae Oy Triphenylethylenes for the prevention and treatment of osteoporosis
GB9604577D0 (en) 1996-03-04 1996-05-01 Orion Yhtymae Oy Serum cholesterol lowering agent
AU5467699A (en) * 1998-08-07 2000-02-28 Chiron Corporation Substituted isoxazole as estrogen receptor modulators
US6219674B1 (en) * 1999-11-24 2001-04-17 Classen Immunotherapies, Inc. System for creating and managing proprietary product data
US6245819B1 (en) 2000-07-21 2001-06-12 Hormos Medical Oy, Ltd. Method for the treatment of vaginal dryness and sexual dysfunction in women during or after the menopause
US6653639B1 (en) * 2000-10-17 2003-11-25 Nikon Corporation Chuck for mounting reticle to a reticle stage
AU2002255593A1 (en) 2001-02-22 2002-09-12 Classen Immunotherapies, Inc. Improved algorithms and methods for products safety
FR2826811B1 (fr) 2001-06-27 2003-11-07 France Telecom Procede d'authentification cryptographique
DE60309465T2 (de) 2002-06-06 2007-08-30 Hormos Medical Ltd. Verfahren zur Hemmung oder Vorbeugung von urogenitaler Atrophie und deren Symptome bei Frauen
US8236861B2 (en) 2004-02-13 2012-08-07 Hormos Medical Corporation Method for enhancing the bioavailablity of ospemifene
US8642079B2 (en) * 2004-02-23 2014-02-04 Hormos Medical Corporation Solid formulations of ospemifene
US20050187302A1 (en) * 2004-02-23 2005-08-25 Hormos Medical Corporation Method for treatment or prevention of osteoporosis in individuals with high bone turnover
US8758821B2 (en) * 2004-05-04 2014-06-24 Hormos Medical Ltd. Oral formulations of ospemifene
US20060293294A1 (en) 2004-09-03 2006-12-28 Hormos Medical Corporation Method for treatment or prevention of androgen deficiency
KR100665758B1 (ko) * 2005-09-15 2007-01-09 제일모직주식회사 반사방지성을 갖는 하드마스크 조성물

Also Published As

Publication number Publication date
US9855224B2 (en) 2018-01-02
HUS1500030I1 (hu) 2015-08-28
ATE387910T1 (de) 2008-03-15
CN1925847A (zh) 2007-03-07
US20120270952A1 (en) 2012-10-25
US20130324614A1 (en) 2013-12-05
NO20151603L (no) 2006-11-03
US20160101065A1 (en) 2016-04-14
US8772353B2 (en) 2014-07-08
DK1713458T3 (da) 2008-07-07
NO20063960L (no) 2006-11-03
EP1713458B1 (en) 2008-03-05
US8236861B2 (en) 2012-08-07
DE602005005165D1 (de) 2008-04-17
LU92736I2 (fr) 2015-08-10
EP1713458A1 (en) 2006-10-25
DE602005005165T2 (de) 2009-04-30
AU2005211958B2 (en) 2010-11-25
ES2302177T3 (es) 2008-07-01
FR15C0041I1 (en, 2012) 2015-07-17
FR15C0041I2 (fr) 2015-11-13
JP5577011B2 (ja) 2014-08-20
AU2005211958A1 (en) 2005-08-25
PL1713458T3 (pl) 2008-08-29
US8470890B2 (en) 2013-06-25
MXPA06009274A (es) 2007-04-16
RU2385716C2 (ru) 2010-04-10
JP2014141533A (ja) 2014-08-07
CY1111014T1 (el) 2015-06-11
US20140303259A1 (en) 2014-10-09
PT1713458E (pt) 2008-05-07
CA2556089C (en) 2013-04-02
BRPI0507661A (pt) 2007-07-17
CA2556089A1 (en) 2005-08-25
NO339190B1 (no) 2016-11-14
WO2005077350A1 (en) 2005-08-25
LTPA2015023I1 (lt) 2015-08-25
DK1713458T5 (da) 2008-09-29
CY2015027I2 (el) 2016-04-13
US20050182143A1 (en) 2005-08-18
JP6023119B2 (ja) 2016-11-09
JP2007522190A (ja) 2007-08-09
US9241915B2 (en) 2016-01-26
CY2015027I1 (el) 2016-04-13
LTC1713458I2 (lt) 2017-06-26
NO337656B1 (no) 2016-05-23
RU2006132719A (ru) 2008-03-20

Similar Documents

Publication Publication Date Title
BE2024C508I2 (en, 2012)
BE2022C549I2 (en, 2012)
BE2023C542I2 (en, 2012)
BE2021C001I2 (en, 2012)
BE2019C506I2 (en, 2012)
BE2019C548I2 (en, 2012)
BE2018C045I2 (en, 2012)
BE2017C063I2 (en, 2012)
BE2020C525I2 (en, 2012)
BE2017C027I2 (en, 2012)
BE2017C023I2 (en, 2012)
BE2017C002I2 (en, 2012)
BE2016C067I2 (en, 2012)
BE2016C014I2 (en, 2012)
BE2015C041I2 (en, 2012)
BE2015C038I2 (en, 2012)
BE2015C014I2 (en, 2012)
BE2015C015I2 (en, 2012)
BE2015C066I2 (en, 2012)
BE2015C065I2 (en, 2012)
FR15C0041I1 (en, 2012)
JP2005203960A5 (en, 2012)
BE2016C042I2 (en, 2012)
BE2016C035I2 (en, 2012)
JP2005292335A5 (en, 2012)